Reports and Releases
FIT Biotech Oy: FIT Biotech’s Chief Scientific Officer to Speak on Attaining Research Milestone and gtGTU Technology
FIT Biotech Oy
Press Release June 8, 2017 at 9:00am EET
FIT Biotech's Chief Scientific Officer to Speak on Attaining Research Milestone and gtGTU Technology
FIT Biotech Oy ("Company") announced that its Chief Scientific Officer, Dr. Santeri Kiviluoto, will speak on June 8 at the Osakesäästäjien keskusliitto conference in Helsinki on an important recent research milestone and the Company's gtGTU technology. The Company had issued a press release on April 4, 2017, regarding improved survival in a validated cancer model for it's gene-based passive immunotherapy. Further information on the conference together with Dr. Kiviluoto's presentation can be found at www.fitbiotech.com.
FIT scientists have engineered the gtGTU vector to express marketed anti-cancer monoclonal antibodies and determined whether they can inhibit tumor growth rate and improve survival in established preclinical cancer models. The objective of this research is to offer an improved alternative to antibody therapies requiring administration by frequent infusions in a hospital setting.
In summary, there was significantly better survival observed when receiving gtGTU DNA expressing an anti-cancer monoclonal antibody. There was also tumor growth inhibition observed in more than 50% of cancer model subjects in the gtGTU group. The difference in tumor growth was statistically significant between gtGTU (anti-cancer monoclonal antibody) compared to negative control gtGTU or non-GTU.
"Attaining this significant milestone represents strong evidence confirming our decision to pursue developing gene-based antibody therapies forecasted multibillion euro sales", says Dr. Santeri Kiviluoto, Chief Scientific Officer of FIT Biotech.
FIT BIOTECH OY
Santeri Kiviluoto, PhD, BSc (Econ & Bus Adm)
Chief Scientific Officer
FIT Biotech Oy
Tel: +46 76 560 71 30
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.